JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Strona główna・Stock List・West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Closed

SectorHealthcare

240.28 -0.43

Buy Sell

Overview

Share price change

24h

Current

Min

239.48

Max

243.35

Key metrics
By Trading Economics
Income	42M 132M
Sales	69M 767M
P/E Sector Avg	35.848 34.393
EPS	1.45
Dividend yield	0.35
Profit margin	17.195
Employees	10,600
EBITDA	48M 199M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.93% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.35% 2.54%
Next Earnings	23 paź 2025

Market Stats
By TradingEconomics
Market Cap	2B 17B
Previous open	240.71
Previous close	240.28

News Sentiment

By Acuity

50%

162 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

213.26 / 219.27 Support & Resistance

West Pharmaceutical Services Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2025, 17:49 UTC

Major Market Movers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 sie 2025, 17:18 UTC

Major Market Movers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 sie 2025, 16:25 UTC

Earnings

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 sie 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 sie 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 sie 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 sie 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 sie 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement 2Q Rev $25.8M >EXOD

11 sie 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 sie 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 sie 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 sie 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 sie 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 sie 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 sie 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 sie 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 sie 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 sie 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Comparison

Price change

West Pharmaceutical Services Inc Forecast

Price Target

By TipRanks

29.93% upside

12 Months Forecast

Average 313.11 USD 29.93%

High 350 USD

Low 245 USD

Based on 10 Wall Street analysts offering 12 month price targets forWest Pharmaceutical Services Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to West Pharmaceutical Services Inc - Dist in the past 3 months.

Technical Score

By Trading Central

213.26 / 219.27Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

162 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.